SCHEMBL6982783

SCHEMBL6982783

CC(C)CC(NC(=O)OC(C)(C)C)C(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.61
GAA P10253 1/20 0.60
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
HRH2 P25021 3/20 0.52
HRH1 P35367 3/20 0.52
KMT2A Q03164 3/20 0.52
MEN1 O00255 1/20 0.52
CTSS P25774 1/20 0.48
CTSK P43235 1/20 0.48
GPR119 Q8TDV5 1/20 0.47
MC4R P32245 1/20 0.47
POLB P06746 1/20 0.46
GFER P55789 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981597 0.89 MAPK1 (0.52) MAPK1GAAALDH1A1LMNAHRH2
SCHEMBL6982596 0.89 SMN1; SMN2 (0.54) MAPK1GAAALDH1A1LMNAHRH2
SCHEMBL6976074 0.89 MAPK1 (0.52) MAPK1GAAALDH1A1LMNAHRH2
SCHEMBL6985297 0.88 ALDH1A1 (0.65) MAPK1GAAALDH1A1LMNAHRH2
SCHEMBL6980930 0.87 MAPK1 (0.59) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL14850779 0.87 KMT2A (0.48) MAPK1GAAHRH2HRH1KMT2A
SCHEMBL6986093 0.86 MAPK1 (0.56) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL9840713 0.86 KMT2A (0.47) MAPK1GAAHRH2HRH1KMT2A
SCHEMBL4974155 0.84 MAPK1 (0.64) MAPK1ALDH1A1LMNAKMT2AMEN1
SCHEMBL9840764 0.84 TGM2 (0.47) MAPK1GAAKMT2AMC4RPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
US-5935959-A CYSTEINE PROTEASE INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 1999-08-10 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
CN-1163145-A Inhibiting agent for vascular formation SENJI SEIYAKU K K (JP) 1997-10-29 CN disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed